NCT05342493 - Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use | Biotech Hunter

Enrollment

1,000

Participants

Timeline

Start Date

April 20, 2022

Primary Completion Date

September 30, 2026

Study Completion Date

June 22, 2029

Conditions

Migraine Disorders

Interventions

DRUG

Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution

The usual adult dose is 225 mg of fremanezumab (genetical recombination) administered subcutaneously as a single dose once every 4 weeks or 675 mg administered subcutaneously as a single dose once every 12 weeks.

Trial Locations (1)

540-0021

RECRUITING

Pharmacovigilance Department, Osaka